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Abstract We describe 131 South African sexual assault
survivors offered HIV post-exposure prophylaxis (PEP).
While the median days completed was 27 (IQR 27, 28),
34% stopped PEP or missed doses. Controlling for baseline
symptoms, PEP was not associated with symptoms
(OR = 1.30, 95% CI = 0.66, 2.64). Factors associated
with unprotected sex included prior unprotected sex
(OR = 6.46, 95% CI = 3.04, 13.74), time since the assault
(OR = 1.33, 95% CI = 1.12, 1.57) and age (OR = 1.30,
95% CI = 1.08, 1.57). Trauma counseling was protective
(OR = 0.18, 95% CI = 0.05, 0.58). Four instances of
seroconversion were observed by 6 months (risk = 3.7%,
95% CI = 1.0, 9.1). Proactive follow-up is necessary to
increase the likelihood of PEP completion and address the
mental health and HIV risk needs of survivors. Adherence
interventions and targeted risk reduction counseling should
be provided to minimize HIV acquisition.
Keywords Human immunodeficiency virus 
Post-exposure prophylaxis  Sexual assault 
Adherence  Risk behavior
Introduction
Antiretroviral therapy reduces HIV transmission risk fol-
lowing needle-stick exposures [1]. Guidelines in many
countries, including South Africa, also recommend post-
exposure prophylaxis (PEP) following potential sexual
exposure to HIV [2–14]. In reports from North America,
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Europe and Australia, PEP acceptance, completion and
HIV testing rates are generally lower following sexual
assault than following consensual sexual exposures [15–
23]. These studies describe Western settings where HIV
prevalence is relatively low in the general public but sub-
stantially higher among the men-who-have-sex-with-men
who have been studied following consensual sexual
exposures. Sexual assault survivors may be more motivated
to accept and adhere to PEP in higher HIV prevalence
areas.
However, rape survivors may be too traumatized when
they seek immediate post-rape care to be able to fully
understand the risks and benefits of PEP [16]. Even in
higher HIV prevalence settings like Kenya and South
Africa, PEP adherence is often poor [24, 25]. In Kenya,
survivors’ willingness to accept and adhere to PEP was
affected by the difficulty clinicians have discussing rape
and encouraging communication with survivors [26]. South
African survivors report that counseling and other forms of
emotional and psychological support are important com-
ponents of PEP provision [27].
As in many countries, South African health care pro-
viders often lack the training to provide quality care for
rape survivors, provider attitudes may be negative, there
are often no post-rape care protocols, service delivery may
be uncoordinated, and there is little trauma counseling and
psychosocial referral [28]. A cross-sectional study of 124
doctors and nurses in all nine South African provinces
found that one-third did not view rape as a serious medical
condition, and less than one-third had ever been trained on
caring for rape survivors [29]. Almost 60% reported that
their hospital did not have a protocol for post-rape care,
and less than half reported that they referred rape survivors
for counseling.
In many countries and localities, facilities that initiate
PEP after sexual assault may refer clients to specialized
local clinics for the remainder of their PEP course and
follow-up. There is usually no formal tracking system
between or within these clinics and there is no active
retention approach. In contrast, when Brazilian sexual
assault survivors were followed in a more structured sys-
tem, PEP completion and follow-up HIV testing rates were
marginally higher than generally reported in the literature
[30]. And in a more recent study at a rural South African
hospital, survivors were three times more likely to com-
plete the entire 28 day course when they received com-
prehensive care from specially trained nurses than in the
pre-intervention period [28].
Maximizing PEP completion and adherence following
sexual assault in South Africa and elsewhere may warrant
the development of proactive follow-up systems. Addi-
tionally, if some assault survivors are also exposed to HIV
through consensual sexual relationships, they may benefit
from risk reduction counseling modeled after that provided
following consensual exposures [22, 23, 31]. Thus, we
designed a proactive, flexible, nurse-driven follow-up
system for sexual assault survivors in Cape Town, South
Africa. Within the context of such proactive follow-up, we
describe PEP adherence and predictors of non-adherence,
symptoms associated with PEP use, predictors of HIV risk
prior to and following the assault, follow-up HIV testing
rates and instances of seroconversion. This information can
be used to continue to improve upon PEP service delivery
systems for sexual assault survivors in South Africa and
elsewhere by identifying survivor characteristics associated
with poorer outcomes and developing and testing new
strategies to improve follow-up and adherence and reduce
subsequent HIV exposures and seroconversion. It also
provides critical information about the level of support
needed to retain sexual assault survivors for ongoing HIV
prevention and testing that can inform public health policy-
makers.
Methods
Study Design
This was an observational study of sexual assault survivors
who were offered 28 days of zidovudine and lamivudine
within 72 h of an assault associated with potential HIV
transmission. PEP, sexually transmitted infection prophy-
laxis and emergency contraception were all provided free
of charge. PEP medications were dispensed as follows: at
the initial clinic visit, a 3 or 4 day supply was provided by
a non-research clinician or a 7 day supply was provided by
a research clinician. At the first clinical follow-up visit for
those seen initially by non-study staff, the remainder of the
first week’s supply was dispensed. At the week one study
visit, the remainder of the full 28-day course was dis-
pensed. Though nurses did not provide formal adherence
counseling, they were encouraged to discuss specific
adherence strategies with participants. Study nurses also
referred participants for rape counseling.
Setting
Initial care was provided in a hospital-based rape treatment
center outside of Cape Town, South Africa by research or
non-research clinicians (depending upon research staff
availability). Follow-up visits with research nurses over the
course of 6 months were offered at the rape treatment
center, a research office in Cape Town, a primary care
health centre in a neighboring township, or at home. Both
the longer duration of follow-up and the choice of multiple
follow-up sites differ from routine practice.
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Participants
We maintained an anonymous record of all sexual assault
survivors presenting for care who were 14 years of age or
older. We enrolled participants for up to 5 days after rape
examination. Sexual assault survivors who had experienced
receptive vaginal or anal intercourse without a condom or
with a condom that broke or came off, receptive oral sex
with ejaculation, or perpetrator blood or ejaculate on a
mucous membrane or non-intact skin were eligible.
Patients found to be infected with HIV by self-report or an
appropriate testing algorithm were excluded. Baseline and
follow-up HIV testing were not required.
Rape center staff recruited participants after clinical and
forensic examinations and provision of the initial PEP
dose. If the initial visit was outside of research hours,
patients were asked to provide written consent to be con-
tacted by telephone and/or home visit for recruitment.
Patients were also recruited at their first routine clinical
follow-up visit. Participation of patients who were between
14 and 18 years of age required guardian consent.
The Committee on Human Research at the University of
California, San Francisco and the Research Ethics Com-
mittee at University of Cape Town approved the study
protocols. Each participant provided written informed
consent.
Demographic Data and Sexual Assault Characteristics
To minimize intrusiveness and interview time, study nurses
obtained demographic data and assault details from stan-
dard medico-legal forms. Additional data were obtained by
interviewer-administered questionnaire.
Measuring Adherence, Symptoms and Risk Behaviors
We calculated the total number of days of PEP completed
at each visit using self-report of the last day that PEP was
taken, and the study record of PEP initiation. Compre-
hension of dosing instructions and reasons for missed doses
were queried. Symptoms and sexual behaviors were elic-
ited with a structured interviewer-administered question-
naire at study enrollment (baseline) and at weeks one and
four and months three and six. Symptoms were graded
using modified World Health Organization criteria. At
week one, study nurses asked about the total number of
partners with whom the participant had protected or
unprotected intercourse (vaginal, oral and anal) in the
6 months prior to the assault. For each unprotected sex
partner, we also asked about the partner’s HIV status.
Interval sexual histories were obtained at subsequent visits.
Laboratory Evaluations
HIV antibody testing, with pre- and post-test counseling,
was offered at baseline and months three and six. Those
who declined HIV testing were encouraged to be tested at
subsequent visits. White blood cell count, hemoglobin and
the liver enzyme aspartate alanine aminotrasferase (ALT)
were measured at baseline, week four, and months three
and six. Female participants were offered pregnancy tests
at enrollment and week four.
Incentives and Follow-up
We provided a 50 Rand (approximately US $8.50) food
voucher at week four and months three and six. For par-
ticipants who did not choose home visits, transportation
costs were reimbursed. With participant consent,
appointment reminders were provided by telephone at
1 week and 1 day prior to visits. For missed visits, follow-
up contact was attempted for up to 5 days, at different
times of day. None of these are the standard, non-research
practice.
Statistical Methods
We used Fisher’s exact test or the t-test in univariate
analyses and multivariable logistic regression models to
examine predictors of PEP non-adherence and post-assault
HIV risk behavior. Non-adherence was defined as either
PEP discontinuation prior to 28 days, self-report of any
missed dose between days 3 and 7, and/or loss to follow-up
prior to the week one study visit. HIV risk behavior was
defined as unprotected vaginal intercourse reported at the
three or 6 month visit.
We included the following variables in all univariate
analyses: age, ethnicity, education, employment, household
income, living/not living with sexual partner, children at
home, pregnancy, perpetrator known, perpetrator was a
husband or boyfriend, prior unprotected intercourse, prior
HIV testing and rape counseling received within one week.
In the adherence model, we also included time to PEP
initiation and symptoms at baseline. In the ongoing HIV
risk behavior models we also included symptoms and
whether rape counseling was received by 4 weeks. Multi-
variable models were constructed using backward selection
of variables associated with a P-value of 0.20 or less in
univariate models. The association of PEP use with
symptoms was assessed in a repeated measures model
using generalized estimated equations.
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Results
Participants, Study Size and Descriptive Data
During the study period of March to September 2004, 514
patients were seen at the rape center. Of these patients, 135
(26%) eligible participants were enrolled; 131 of those
(97%) initiated PEP. Of the 514, 103 (20%) were seen after
hours and did not provide consent to be contacted and 59
(14%) declined study participation. Eight (2%) did not
have an eligible exposure, 60 (17%) were not contacted
within 5 days of the initial exam, 28 (8%) were less than
14 years old, 15 (4%) between 14 and 18 years old did not
obtain guardian consent, 13 (4%) were unable to follow up
and 14 (4%) were unable to consent. Data were unavailable
for the remaining 79 non-study patients. Characteristics of
the 135 study participants are shown in Table 1.
Assaults often involved abduction and violence
(Table 2). Forty-six percent of perpetrators were known,
commonly being neighbors, friends or ex-boyfriends. The
perpetrator’s HIV status was usually unknown (97%). Anal
or oral penetration was reported infrequently.
PEP Initiation and Adherence
The median time to PEP initiation was 13 h [IQR 8, 22].
PEP was initiated within less than 24 h in 103 (79%)
Table 1 Participant characteristics
Characteristics Participants
Age, years (median; IQR) 21; [17–24]
Female sex, n (%) 132 (98)
Race/ethnicity, n (%)
African 103 (76)
‘‘Colored’’ 32 (24)
Primary language, n (%)
Xhosa 101 (75)
Afrikaans 26 (19)
English 6 (5)
Zulu 2 (1)
Marital status, n (%)
Single/never married 116 (86)
Married 5 (4)
Separated 6 (4)
Divorced 6 (4)
Live-in partner 2 (1)
Children, n (%)
None 87 (64)
1–2 41 (30)
C3 7 (6)
Participant’s children living in home, n (%) 33 (24)
Any others living in home (median; IQR) 5; [3, 6]
Pregnant at enrollment, n (%) 4 (3)
Education, n (%)
None through grade 6 10 (7)
Grade 7–11 104 (77)
High school graduate 11 (8)
College/university/graduate school 10 (9)
Employed, n (%) 29 (21)
Household income (Rand), n (%) (R1 = US$6)
BR5,000 19 (14)
R5,001–10,000 30 (22)
R10,001–20,000 36 (27)
R10,001–30,000 22 (16)
R30,001–40,000 14 (10)
[R40,000 14 (10)
Table 2 Characteristics of the assault and potential HIV exposure
Characteristic N (%)
Any perpetrator known to participant 84 (46)
Neighbor 20 (15)
Friend 17 (13)
Previous boyfriend 8 (6)
Lives with perpetrator 5 (4)
Abducted 77 (57)
Location of assault
Perpetrator’s home 55 (41)
Open space 45 (33)
Participant’s home 17 (13)
Other 18 (13)
Any weapon used 68 (50)
Gun 29 (21)
Knife 30 (39)
Bottle/screwdriver/other 16 (12)
Alcohol use in 3 h prior to assault 34 (25)
Alcohol use between 3 and 24 h of assault 3 (2)
Drug use within 24 h of assault 3 (2)
Potential HIV exposure routea
Vaginal receptive intercourse 128 (97)
Anal receptive intercourse 20 (15)
Oral receptive intercourse with ejaculation 5 (4)
Unconscious at time of assault 4 (3)
Total perpetrators 193
Number of perpetrators
1 102 (76)
2 21 (16)
[2 12 (9)
HIV status of perpetrator unknown 187 (97)
Prior intercourse with any perpetrator 13 (10)
a No condom used or condom broke or came off
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participants. The median days of PEP completed was 27
[IQR 27, 28]. However, 34% of participants had either
stopped taking PEP, missed one or more doses on days 3–7,
or were lost to follow-up prior to the week one study visit
(Table 3). Nineteen (15%) participants reported missing
two or more doses in the prior week. Reasons commonly
cited for missed doses included forgetting and being away
from home. All participants reported good understanding
of dosing instructions. In univariate analyses, there was a
non-significant trend towards better adherence among those
with more education and those who reported attending rape
counseling (P = 0.090 and 0.129, respectively). These
trends were stronger in the multivariate model (P = 0.057
and 0.069). No other variables were associated with
adherence.
Symptoms and Laboratory Abnormalities
Symptoms were reported by 70% of participants, most
commonly fatigue, nausea and headaches. The median time
to study enrollment and initial symptom data collection
was 3 days [IQR 2, 3] following PEP initiation. At the
baseline study visit, significantly more participants who
had not yet initiated PEP, or had initiated PEP within the
previous 24 h, reported symptoms compared to participants
who had initiated PEP more than 24 h prior (52% versus
17%; P = 0.003, Table 4). In multivariate logistic regres-
sion models controlling for baseline symptoms, PEP was
not associated with on-treatment symptoms (OR = 1.30,
95% CI = 0.66, 2.64). Symptoms at baseline were asso-
ciated with subsequent symptoms in models including all
participants who took PEP (OR = 2.68, 95% CI = 1.25,
5.74) and when restricting the analysis to just those 23
participants who had not yet initiated PEP or had initiated
PEP within 24 h of the baseline visit (OR = 8.03, 95%
CI = 1.8, 35.5). There were no laboratory abnormalities
more severe than Grade 2 in any participants taking PEP.
Four participants were pregnant at enrollment. A total of
six incident pregnancies were detected by the 6 month
visit.
HIV Risk Behaviors
In the 6 months prior to the assault, 71 (58%) participants
reported vaginal intercourse, which was unprotected in fifty
participants. Among these, 32 (64%) did not know the HIV
status of their partners. At week four, 44 participants (38%)
reported having any intercourse since the prior visit, 61%
of whom reported unprotected vaginal intercourse. Half of
these cases did not know the HIV status of their partners.
Table 3 PEP adherence
Adherence characteristic N (%)
Lost to follow-up at week 1, discontinued,
or missed any dose
45 (34)
Lost to follow-up at week 1a 9 (7)
Discontinued PEP before 28 daysb 7 (5)
Missed any dose in 4 days prior to week 1 visit 29 (25)
1 dose 10 (8)
2 doses 12 (9)
C3 doses 7 (5)
PEP dosing beyond 28 days and no missed doses
at week 1
4 (3)
Lost to follow-up between weeks 1 and 4 with all
PEP dispensed
18 (14)
Reasons for any missed dose in prior 4 days at week 1 visit
Forgot 18 (62)
Away from home 14 (54)
Didn’t want people to notice 5 (17)
Felt sick 5 (17)
Busy 4 (14)
Change in routine 3 (10)
Side effects 2 (7)
Slept through dose 2 (7)
Felt depressed 2 (7)
Thought pills would work even if a few were
missed
1 (3)
Feeling overwhelmed 0
Pill burden 0
a 10–12 days of medications had been dispensed to the nine partic-
ipants who were lost to follow-up prior to the week 1 visit
b 1 additional participant discontinued PEP after 2 days at the
direction of the study physician and is not considered non-adherent
Table 4 Proportion of participants reporting Cgrade 2 symptoms stratified by PEP initiation within 24 h of interview
Characteristic Baseline
(n = 135) %
Week 1
(n = 123) %
Week 4
(n = 117) %
Month 3
(n = 116) %
Month 6
(n = 104) %
Any symptom 46 34 27 24 32
PEP not yet initiated/initiated
within 24 h (n = 23)
52 48 23 30 25
PEP initiated [24 h prior (n = 112) 17 31 28 23 31
P-value 0.003 0.147 0.791 0.426 0.787
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At months three and six, increasing proportions of partic-
ipants reported intercourse. This was mostly unprotected
and with partners of unknown HIV status (Table 5). In the
multivariate model, factors associated with unprotected sex
in the 6 months following the assault included unprotected
sex in the 6 months prior to the assault (OR = 6.46, 95%
CI = 3.04, 13.74), time since the assault (per 30-day
increments, OR = 1.33, 95% CI = 1.12, 1.57) and age
(per 5-year increments OR = 1.30, 95% CI = 1.08, 1.57,
Table 6). Attending trauma counseling was protective
(OR = 0.18, 95% CI = 0.05, 0.58).
Baseline and Follow-up HIV Testing
and Seroconversion
Two participants declined HIV testing at baseline but
accepted it at their next visits. Testing was declined by
three and 16 participants at months three and six, respec-
tively. Those who declined cited not wanting to know their
HIV status, an inability to cope with a positive result, or too
short a time since the last test. In total, 81% of participants
had an HIV test at months three or six. Four seroconver-
sions were observed by 6 months (risk = 3.7%; 95%
CI = 1.0, 9.1). Two occurred in participants who did not
report other unprotected sex and thus were likely PEP
failures. One of these occurred in the context of excellent
reported adherence and the other with incomplete adher-
ence to PEP. The other instances were likely to have
resulted from ongoing exposures.
Service Delivery Issues
Sixty-one percent of follow-up visits occurred at the rape
treatment center, twenty percent at home, and 19% at the
research office in town. Missed visit tracing was required
for 52 participants; 161 tracing attempts resulted in 45
participants returning for follow-up. Those participants
missing visits cited being too busy, work-related issues,
forgetting, family problems, having moved, transportation/
money problems and school-related issues.
Table 5 Sexual behavior
Baseline
(n = 123) %
Week 4
(n = 117) %
Month 3
(n = 116) %
Month 6
(n = 104) %
Any sexual intercourse, % all 58 38 53 64
1 partner, % sexually active 93 100 98 97
Unprotected intercourse,
% sexually active
70 61 62 60
Partner HIV status unknown,
% unprotected intercourse
64 50 82 82
Table 6 Predictors of
unprotected sexual intercourse
in the 6 months following the
assault
Characteristic Unadjusted odds ratio (95% CI) P-value
Age 1.04 (1.02, 1.07) 0.000
Primary language 1.00 (0.65, 1.57) 0.969
Education 1.084 (0.639, 1.841) 0.764
Employed 0.381 (0.244, 0.594) 0.000
Income 0.697 (0.462, 1.051) 0.085
Living with primary sexual partner 4.33 (1.71, 11.0) 0.002
Pregnant at enrollment 0.093 (0.020, 0.432) 0.002
Any perpetrator known to participant 0.82 (0.56, 1.21) 0.323
Perpetrator was husband or boyfriend 0.79 (0.39, 1.59) 0.506
Unprotected intercourse prior to assault 15.5 (9.48, 25.34) 0.000
Symptoms (Cgrade 2) 1.23 (0.811, 1.85) 0.334
Attended trauma counseling 0.64 (0.43, 0.94) 0.024
Time since assault 1.00 (0.998, 1.004) 0.476
Characteristic Adjusted odds ratio (95% CI) P-value
Age (per 5 year increments) 1.30 (1.08, 1.57) 0.006
Unprotected intercourse prior to assault 6.46 (3.04, 13.74) 0.000
Attended trauma counseling 0.18 (0.05, 0.58) 0.004
Time since assault (in 30 day increments) 1.33 (1.12, 1.57) 0.001
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At least one rape counseling session was attended by 75
(56%) participants. At the baseline visit, staff referred 128
(95%) individuals for rape counseling; 61 (50%) of those
who completed the week one visit attended counseling. At
week one, week four and month three, 104 (90%), 79
(81%), 46 (98%) participants attending each visit had been
referred, respectively; 67 (64%), 52 (64%), and 28 (61%)
subsequently attended rape counseling.
Discussion
When PEP and rape counseling referrals were provided by
nurses trained in intensive follow-up, PEP completion and
follow-up HIV testing rates were very high; 74% were
known to have completed the full PEP course and an
additional 14% received the entire 28 day course and may
have completed it even though they were lost to follow-up.
Still, 25% of participants reported missing at least one dose
in the prior 4 days in the first week of therapy. This study’s
findings are consistent with a study of PEP following
consensual sexual exposure in San Francisco, in which
16% of participants reported missing one or more doses in
the 4 days prior to the week one visit and 78% completed
the 28-day course [22]. There were no predictors of non-
adherence in our study that would suggest targeting
adherence intervention to specific PEP users. Our findings
suggest that all users of PEP need adherence interventions
that address the importance of taking each medication
dose, not just completing 28 days of therapy.
Studies of PEP following consensual sex often focus on
the potential for behavioral disinhibition, though reductions
in risk behavior have been reported in the context of risk
reduction counseling [31]. No studies address continuing
HIV risk among sexual assault survivors or examine pre-
existing HIV-risk behavior patterns. In our study, baseline
and ongoing HIV sexual risk behaviors were common and
probably resulted in HIV acquisition in two participants.
We found that the primary predictor of ongoing unpro-
tected intercourse, which was very common, was prior
unprotected intercourse. We believe that sexual assault
survivors should have an assessment of their HIV risk
history and should receive risk reduction counseling as
appropriate during their post-rape care follow-up.
While reported symptoms are frequent in the PEP lit-
erature, there are no randomized studies examining this
issue. Our study design, however, provided an opportunity
to compare symptoms in participants who had been on PEP
for 1–5 days with a group that had been on PEP for less
than 24 h or not at all. We found that the baseline symptom
rate was higher in the group with no or less PEP exposure
at baseline, and then rates of reported symptoms during and
after PEP completion equalized between both groups.
These intriguing findings suggest that many symptoms
reported in PEP users may be related to the emotional
impact of potential HIV exposure and trauma rather than
the drugs themselves, at least with this specific two-drug
regimen. Discussing this information with patients being
offered PEP may help to normalize their experience. If
providers understand this phenomenon, they may be better
able to support their clients during their PEP course. This
finding also highlights the importance of offering rape
survivors appropriate psychosocial support, which may
help them understand and cope with psychosomatic com-
ponent of their symptoms that could otherwise impact their
PEP adherence.
Substantial resources were required to achieve high
follow-up and PEP completion rates. These included nurses
who were comfortable with sexual assault and HIV issues,
proactive follow-up, financial support for transportation,
and flexible follow-up locations. The only literature
reporting high follow-up rates are prospective studies and a
study describing another proactive follow-up system in
Amsterdam [32–34]. It is important to consider the
resources required to provide comprehensive follow-up
services when deciding to develop systems to initiate PEP.
The resource-intensive task of developing systems to
provide access to expensive PEP medications, adherence
and risk reduction counseling, and follow-up create a
public health prioritization challenge, especially given that
the efficacy of non-occupational PEP is unproven. How-
ever, these data and other studies do illustrate that, even in
the context of PEP provision, risky sexual behaviors and
seroconversions occur [29]. Therefore, PEP-related ser-
vices should be provided in the context of comprehensive
sexual assault, trauma and HIV prevention services to
minimize HIV acquisition for sexual assault survivors.
Specifically, early risk assessment and risk reduction
counseling would provide an opportunity to address the
larger context of HIV risk. Finally, sexual assault survivors
who use PEP should be counseled that symptoms are
common, usually subside over time, and may be related to
stress. Normalizing this experience can reduce fear
regarding potential PEP toxicity and may improve
adherence.
Limitations of this study included a lack of randomi-
zation, limiting inferences about symptom association with
PEP use. Additionally, while the regimen used in this study
is likely to be the one available in resource-limited settings,
it is being replaced by simpler regimens with less toxicity,
limiting the ability to generalize these findings to more
resource-rich contexts. We did not obtain consent to
describe those who did not enroll in the study (i.e. how
many patients were already HIV positive). The participants
may have exhibited some degree of recall bias. Participants
may also have exhibited a degree of response bias in that
996 AIDS Behav (2012) 16:990–998
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they might have offered responses that they felt pleased the
interviewer.
Further research is needed to develop effective adher-
ence counseling strategies for this population. This is
particularly challenging since PEP may not always be
initiated by providers with specialized training. Further
research is also needed to develop effective risk assessment
and risk reduction counseling strategies following sexual
assault.
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